Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Dissecting the mechanism of action of spiperone, a candidate of drug repurposing for colorectal cancer

ABSTRACT: Dissecting the mechanism of action of spiperone, a candidate of drug repurposing for colorectal cancer

PROVIDER: PRJNA785832 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17114355_1.fastq.gz	Fastqsanger.gz
	SRR17114355_2.fastq.gz	Fastqsanger.gz
	SRR17114356_1.fastq.gz	Fastqsanger.gz
	SRR17114356_2.fastq.gz	Fastqsanger.gz
	SRR17114357_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Dissecting the mechanism of action of spiperone, a candidate of drug repurposing for colorectal cancer

Project description:We evaluated the modulation of mRNA upon spiperone treatment in colorectal cancer epithelial cell line (HCT116) and colorectal cancer stem cells (CRC-SC#1)

2022-02-08 | GSE190093 | GEO

Machine Learning Identifies Candidates for Drug Repurposing in Alzheimer's Disease

Project description:Clinical trials of novel therapeutics for Alzheimer's Disease (AD) have consumed a large amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA) for another indication is a more rapid and less expensive option. In this study, we profile 80 FDA-approved and clinically tested drugs in neural cell cultures, with the goal of producing a ranked list of possible repurposing candidates.

2021-01-14 | GSE164788 | GEO

Systems immunology-based drug repurposing framework to target inflammation in atherosclerosis [Tissue_RNA-seq]

Project description:we present a novel path to drug repurposing to identify new immunotherapies for ASCVD. The integration of time of-flight mass cytometry (CyTOF) and RNA-sequencing identified unique inflammatory signatures in peripheral blood mononuclear cells (PBMCs) stimulated with ASCVD plasma. By comparing these inflammatory signatures to large-scale gene expression data from the LINCS L1000 dataset, we identified drugs that could reverse this inflammatory response. In conclusion, a systems immunology-driven drug repurposing with pre- clinical validation strategy can aid the development of new cardiovascular immunotherapies.

2023-04-23 | GSE230216 | GEO

Systems immunology-based drug repurposing framework to target inflammation in atherosclerosis [RNA-seq_PBMC]

2023-04-23 | GSE230214 | GEO

Systems immunology-based drug repurposing framework to target inflammation in atherosclerosis [DRUG_RNA-seq]

2023-04-23 | GSE230215 | GEO

Development of a Large-Scale Chemogenomics Database to Improve Drug Candidate Selection

Project description:Development of a Large-Scale Chemogenomics Database to Improve Drug Candidate Selection and to Understand Mechanisms of Chemical Toxicity and Action These data support the publication titled "Development of a Large-Scale Chemogenomics Database to Improve Drug Candidate Selection and to Understand Mechanisms of Chemical Toxicity and Action" Copyright (c) 2005 by Iconix Pharmaceuticals, Inc. Guidelines for commercial use: http://www.iconixbiosciences.com/guidelineCommUse.pdf Keywords: other

2005-05-31 | E-GEOD-2409 | biostudies-arrayexpress

Development of a Large-Scale Chemogenomics Database to Improve Drug Candidate Selection

2005-06-01 | GSE2409 | GEO

20230905 ReFRAME drug repurposing collection DDA spectra

Project description:DDA analysis of 14,000 drugs in the ReFRAME drug repurposing collection. Positive and negative ionizations.

| MSV000092822 | MassIVE

Drug Repurposing Using Molecular Network Analysis Identifies Janus Kinase as Targetable Driver in Necrobiosis Lipoidica

Project description:Drug repurposing is an attractive strategy for therapy development, particularly in rare diseases where traditional drug development approaches may be challenging due to high cost and small numbers of patients. Here we used a novel drug identification and repurposing pipeline to identify candidate targetable drivers of disease and corresponding therapies through application of causal reasoning using a combination of open-access resources and transcriptomics data. We optimized our approach on psoriasis as a disease model, demonstrating the ability to identify known and novel molecular drivers of psoriasis and link them to current and emerging therapies. Application of our approach to a cohort of tissue samples of necrobiosis lipoidica, an unrelated, rare, and to date molecularly poorly characterized cutaneous inflammatory disorder, identified a unique set of upstream regulators, particularly highlighting the role of IFNG and the JAK-STAT pathway as a likely driver of disease pathogenesis and linked it to JAK inhibitors as potential therapy. Analysis of an independent cohort of NL samples validated these findings with the overall agreement of drug matched upstream regulators above 96%. These data highlight utility of our approach in rare diseases and offer a novel opportunity for drug discovery in other rare diseases in dermatology and beyond.

2024-05-15 | GSE267132 | GEO

Drug screening in Drosophila for repurposing in neuropsychiatry

Project description:Drug screening in Drosophila for repurposing in neuropsychiatry

| PRJNA596785 | ENA